Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 275 of 1048 entries
View as:

Neoadjuvant Therapy With Ivonescimab Combined With Chemotherapy for Triple-Negative Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06977542 Org: User:
Start: 06/30/25 End: 01/31/32 Due: 01/31/33

MammaPrint Value for Pre-menopausal Breast Cancer Patients

Phase: N/A Priority: Normal
NCT ID: NCT05474391 Org: User:
Start: 07/15/22 End: 07/15/24 Due: 07/15/25

Multimodal Model for Efficacy Prediction Cetuximab in Colorectal Cancer Liver Metastasis Patient

Phase: N/A Priority: Normal
NCT ID: NCT05873972 Org: User:
Start: 06/01/23 End: 12/31/24 Due: 12/31/25

Real-world Effectiveness and Safety Study of Sacituzumab Govitecan in Chinese Metastatic Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06356519 Org: User:
Start: 03/01/24 End: 04/01/25 Due: 04/01/26

Effectiveness of Gut Microbiota-targeted Diatery Intervention Among People Living With HIV

Phase: N/A Priority: Normal
NCT ID: NCT06498401 Org: User:
Start: 07/20/24 End: 04/30/25 Due: 04/30/26

QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Early High-Risk TNBC Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06404736 Org: User:
Start: 05/07/24 End: 11/07/30 Due: 11/07/31

Surgical Pleth Index: Predicting the Optimal Timing for Tracheal Intubation During General Anesthesia

Phase: N/A Priority: Normal
NCT ID: NCT04608240 Org: User:
Start: 09/30/20 End: 11/30/21 Due: 11/30/22

Docetaxel With or Without Metronomic Cyclophosphamide as First Line Chemotherapy in Metastatic Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01526499 Org: User:
Start: 12/31/11 End: 07/31/13 Due: 07/31/14

Study Comparing HAI Plus Chemotherapy and Chemotherapy Alone in Patients With Unresectable CRLM

Phase: N/A Priority: Normal
NCT ID: NCT03125161 Org: User:
Start: 04/30/17 End: 12/31/20 Due: 12/31/21

Evaluating the Clinical Value of Traditional Chinese Medicine in the Adjuvant Therapy of Triple-negative Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT04403529 Org: User:
Start: 05/25/20 End: 05/31/24 Due: 05/31/25

Clinical Efficacy of QYHJ and Standard Chemotherapy in the Treatment of Advanced Pancreatic Cancer

Phase: N/A Priority: Normal
NCT ID: NCT05840341 Org: User:
Start: 05/01/23 End: 12/30/25 Due: 12/30/26

Whole Breast Irradiation With Intensity Modulated Radiotherapy and Simultaneously Integrated Boost for Early Stage Breast Cancer Patients

Phase: N/A Priority: Normal
NCT ID: NCT01394575 Org: User:
Start: 07/31/11 End: 07/31/13 Due: 07/31/14

Physical and Psychological Effects of Different Temperature-controlled Breast Prostheses on Patients With Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03830294 Org: User:
Start: 10/10/16 End: 06/30/17 Due: 06/30/18

Adjuvant Chemotherapy of Three-step Regimen in BRCA1/2 Wide Type Ovarian Cancer (ACTS-2)

Phase: N/A Priority: Normal
NCT ID: NCT04520074 Org: User:
Start: 10/08/21 End: 09/30/30 Due: 09/30/31

Incision Pain and Uterine Contraction Pain After Cesarean Section

Phase: N/A Priority: Normal
NCT ID: NCT02595333 Org: User:
Start: 11/30/15 End: 12/31/17 Due: 12/31/18

Preconceptional Thyroid Screening and Childhood Nerocognitive Function

Phase: N/A Priority: Normal
NCT ID: NCT01744743 Org: User:
Start: 01/31/11 End: 12/31/15 Due: 12/31/16

Endostar Combined With IP Second-line Treatment of Advanced Esophageal Squamous Cell Carcinomas

Phase: N/A Priority: Normal
NCT ID: NCT03797625 Org: User:
Start: 05/04/17 End: 12/31/21 Due: 12/31/22

Induction Chemotherapy and Toripalimab Followed by Radiotherapy in Unresectable Laryngeal/Hypopharyngeal Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT05420597 Org: User:
Start: 04/07/21 End: 12/31/25 Due: 12/31/26

A Trial of High Intensity Versus Low Intensity Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01064999 Org: User:
Start: 03/31/10 End: 12/31/14 Due: 12/31/15

GEMOX Combined With Donafenib and Tislelizumab in Advanced Biliary Tract Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT05668884 Org: User:
Start: 10/18/22 End: 03/31/27 Due: 03/31/28

A Phase Ib/II Clinical Study Evaluating the Safety and Efficacy of Tislelizumab in Combination With Golidocitinib and Selinexor for the Treatment of R/R NKTCL

Phase: N/A Priority: Normal
NCT ID: NCT06966154 Org: User:
Start: 05/26/25 End: 05/30/28 Due: 05/30/29

Dalpiciclib, Fulvestrant, Trastuzumab and Pertuzumab in HR Positive, HER2 Positive Metastatic Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT05574881 Org: User:
Start: 09/01/22 End: 01/01/25 Due: 01/01/26

A Phase II Clinical Study of Multimodal Ablation Combined With Systemic Drug Therapy for Advanced Solid Tumors.

Phase: N/A Priority: Normal
NCT ID: NCT06889610 Org: User:
Start: 04/28/25 End: 05/01/28 Due: 05/01/29

Artificial Intelligence Assisted Breast Ultrasound in Breast Cancer Screening

Phase: N/A Priority: Normal
NCT ID: NCT06521788 Org: User:
Start: 09/01/20 End: 12/31/23 Due: 12/31/24

MRD-Guided Surveillance in Resectable Stage IV Metastatic Colorectal Cancer (SURVEILLANCE-II)

Phase: N/A Priority: Normal
NCT ID: NCT06879886 Org: User:
Start: 08/01/25 End: 07/31/28 Due: 07/31/29